Implications of aspirin biochemistry in the pathobiology of ischemic cerebrovascular disease

I have read, with great interest, a recently published article in the Journal of Neurological Sciences by Li et al. titled ‘The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: A meta-analysis of randomized controlled trials’ . The authors performed a meta-analysis of five randomized controlled trials (RCT) comparing combined aspirin and clopidogrel dual antiplatelet therapy (DAT) to aspirin monotherapy (AM) for secondary stroke prevention in symptomatic patients. The number of patients in each treatment arm was similar with 4318 patients in the DAT cohort and 4304 patients in the AM cohort. The mean follow-up of the five RCTs ranged from 1.3 to 3.5years (mean 2.3years). The mean patient age was 65 with a two-thirds predominance of males.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letters to the Editor Source Type: research